5-(3,4-diethoxyphenyl)-3-(2-methylbenzofuran-5-yl)-1,2,4-oxadiazole | 1220973-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3,4-diethoxyphenyl)-3-(2-methylbenzofuran-5-yl)-1,2,4-oxadiazole
• 英文别名: 5-(3,4-diethoxyphenyl)-3-(2-methyl-1-benzofuran-5-yl)-1,2,4-oxadiazole
• CAS: 1220973-61-4
• 化学式: C₂₁H₂₀N₂O₄
• 分子量: 364.401
• InChiKey: OZNJICCZRWUDJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  70.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N'-hydroxy-2-methyl-1-benzofuran-5-carboximidamide 、 3,4-二乙氧基苯甲酸 、 N-hydroxy-3-iodo-4-isopropoxybenzimidamide 、 3-氯-4-丙氧基苯甲酸 以respectively, in Example 36, Step B, the similar procedure afforded the title compound in 6% yield的产率得到5-(3,4-diethoxyphenyl)-3-(2-methylbenzofuran-5-yl)-1,2,4-oxadiazole
  参考文献：
  名称：

  S1P receptors modulators and their use thereof

  摘要：

  本发明涉及具有SIP受体调节活性的新化合物。此外，本发明涉及一种药物，该药物包括本发明中的至少一种化合物，用于治疗由不适当的SIP受体调节活性或表达引起或相关的疾病和/或病症，例如自身免疫反应。本发明的另一个方面涉及使用包含本发明中的至少一种化合物的药物制造药物，用于治疗由不适当的SIP受体调节活性或表达引起或相关的疾病和/或病症，如自身免疫反应。

  公开号：

  US09193716B2

文献信息

• [EN] S1P RECEPTORS MODULATORS AND THEIR USE THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010043000A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及包括本发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如自身免疫反应。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2014063199A1

  公开（公告）日：2014-05-01

  Novel benzofuran derivatives are disclosed. The derivatives have S1P1 receptor activity and/or disease modifying activity and find use in the treatment of conditions or diseases associated with the immune, vascular and nervous systems in animals and/or humans

  揭示了新型苯并呋喃衍生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性，并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。
• S1P Receptors Modulators and Their Use Thereof
  申请人：Gill Gurmit S.

  公开号：US20110318388A1

  公开（公告）日：2011-12-29

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  本发明涉及具有S1P受体调节活性的新化合物。此外，本发明涉及包括本发明中至少一种化合物的药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。
• S1P RECEPTORS MODULATORS AND THEIR USE THEREOF
  申请人：AKAAL PHARMA PTY LTD.

  公开号：US20160038455A1

  公开（公告）日：2016-02-11

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  本发明涉及具有S1P受体调节活性的新化合物。此外，本发明涉及一种制药组合物，包括本发明中的至少一种化合物，用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症，例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中的至少一种化合物的制药组合物制造用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症，例如自身免疫反应的药物。
• S1P RECEPTORS MODULATORS AND USE THEREOF
  申请人：Akaal Pharma Pty Ltd

  公开号：EP2344484B1

  公开（公告）日：2016-06-08